Data shows new therapy successfully targets solid tumours
Drug Discovery World
APRIL 18, 2023
While the global proteasome inhibitors market is expected to reach nearly $2.3 billion by 2026, these drugs are primarily indicated for the treatment of multiple myeloma. AVA3996 is in pre-clinical development with the aim of submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024.
Let's personalize your content